The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Press release from Business Wire

Alexion Reports Second Quarter 2010 Results

<p class=' bwtextaligncenter'> <i><b>- Continued Steady Addition of New Patients on Soliris® in U.S. and Europe -</b></i> </p> <p class=' bwtextaligncenter'> <i><b>- Reiterating Upward Revisions to 2010 Sales and Non-GAAP EPS Guidance Announced in June -</b></i> </p> <p class=' bwtextaligncenter'> <i><b>- Current aHUS Trials Fully Enrolled; Data Expected by Year-End -</b></i> </p> <p> <b>Second Quarter 2010 -- Selected Highlights:</b> </p> <p> Financial: </p> <ul> <li class='bwlistitemmarginbottom'> Soliris<sup>®</sup> (eculizumab) net product sales increased 36 percent to $125.8 million in Q2 2010, compared to $92.3 million in Q2 2009. </li> <li class='bwlistitemmarginbottom'> Q2 GAAP net income increased 30 percent to $21.8 million, or $0.24 per share, compared to GAAP net income of $16.8 million, or $0.19 per share, in Q2 2009. </li> <li class='bwlistitemmarginbottom'> Q2 non-GAAP net income increased 56 percent to $36.9 million, or $0.39 per share, compared to non-GAAP net income of $23.8 million, or $0.26 per share, in Q2 2009. </li> </ul> <p> Development: </p> <ul> <li class='bwlistitemmarginbottom'> Soliris received regulatory and reimbursement approvals in Japan. </li> <li class='bwlistitemmarginbottom'> Enrollment completed in current clinical studies of Soliris as a treatment for patients with aHUS. </li> <li class='bwlistitemmarginbottom'> Data presentations further support aHUS and transplant programs. </li> </ul> <p class=' bwtextaligncenter'> </p>

Thursday, July 22, 2010

Alexion Reports Second Quarter 2010 Results06:30 EDT Thursday, July 22, 2010 CHESHIRE, Conn. (Business Wire) -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced financial results for the three and six months ended June 30, 2010. Second Quarter 2010 Financial Results: For the three months ended June 30, 2010, Alexion Pharmaceuticals, Inc. (“Alexion” or the “Company”) reported total revenues of $125.8 million from net product sales of Soliris® (eculizumab), compared to $92.3 million in Q2 2009, reflecting ongoing steady additions of new patients in the U.S. and in European countries during the quarter. Soliris is the only drug specifically indicated for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, debilitating and life-threatening blood disorder. Soliris was approved by the U.S. Food and Drug Administration and the European Commission in 2007, and by Japan's Ministry of Health, Labour and Welfare (MHLW) in 2010. Alexion's non-GAAP operating results are equal to its GAAP operating results less only share-based compensation and non-cash tax expense. Non-cash tax expense represents the reduction in cash taxes attributable to the utilization of U.S. net operating losses (NOL's). The following summary table is provided for investors' convenience. (in thousands, except per share data) (unaudited)               Three Months EndedSix Months EndedJune 30,June 30,   2010     2009   2010     2009   Total revenues $ 125,834 $ 92,256 $ 243,412 $ 173,523   GAAP net income $ 21,773 $ 16,802 $ 42,707 $ 31,308   Share-based compensation 8,250 6,948 16,354 14,874 Non-cash tax expense 6,923 - 12,439 -         Non-GAAP net income $ 36,946 $ 23,750 $ 71,500 $ 46,182   Shares used in computing diluted earnings per share (GAAP) 92,575 90,159 92,340 89,975 Shares used in computing diluted earnings per share (Non-GAAP) 93,852 91,236 93,611 91,107   GAAP earnings per share - diluted $ 0.24 $ 0.19 $ 0.46 $ 0.35 Non-GAAP earnings per share - diluted $ 0.39 $ 0.26 $ 0.76 $ 0.51   Second Quarter 2010 Non-GAAP Financial Results: The Company reported non-GAAP net income for Q2 2010 of $36.9 million, or $0.39 per share, an increase of 56 percent compared to $23.8 million, or $0.26 per share, in Q2 2009. Non-GAAP earnings per share in Q2 2009 included a non-cash charge of $3.4 million, or $0.04 per share, associated with the exchange of convertible notes during the quarter. Alexion's non-GAAP operating expenses for Q2 2010 were $71.8 million, compared to $54.0 million for Q2 2009. Non-GAAP research and development (R&D) expenses for Q2 2010 were $21.7 million, compared to $16.5 million for Q2 2009. The increase in R&D expenses primarily reflected the Company's expanded clinical development programs. Non-GAAP selling, general and administrative (SG&A) expenses for Q2 2010 were $50.1 million, compared to $37.6 million for Q2 2009. The increase in SG&A expenses primarily reflected costs associated with the expansion of the Company's operations worldwide. Second Quarter 2010 GAAP Financial Results: The Company reported GAAP net income for Q2 2010 of $21.8 million, or $0.24 per share, an increase of 30 percent compared to $16.8 million, or $0.19 per share, in Q2 2009. GAAP earnings per share in Q2 2009 included a non-cash charge of $3.4 million, or $0.04 per share, associated with the exchange of convertible notes during the quarter. Alexion's GAAP operating expenses for Q2 2010 were $79.8 million, compared to $61.0 million for Q2 2009. GAAP R&D expenses for Q2 2010 were $23.7 million, compared to $18.3 million for Q2 2009. GAAP SG&A expenses were $56.1 million for Q2 2010, compared to $42.7 million for Q2 2009. As of June 30, 2010, the Company had $248.8 million in cash, cash equivalents and marketable securities, compared to $204.7 million at March 31, 2010. “Our achievements in the second quarter, including landmark accomplishments in Japan and impressive progress in our lead pipeline programs, reflect clinical benefits provided by the innovative complement-blockade technology of Soliris, and the continued strengthening of our growing global operations,” said Leonard Bell, M.D., Chief Executive Officer of Alexion. “We look forward to the opportunity to serve more patients with PNH in the coming quarters, while progressing our aHUS and transplant programs to serve patients with other severe and ultra-rare disorders in the years ahead.” Second Quarter 2010 Research and Development Progress: During the second quarter, Alexion made continued progress on advancing the development of Soliris as a treatment for patients suffering from additional rare and severe complement-mediated disorders. There are currently 12 clinical trials of Soliris underway in eight diseases, and the Company is increasingly focused on its two lead areas of nephrology and transplant. PNH: Approvals and Continuing Research On June 2, 2010, the Company announced that the launch of Soliris as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than expected, as a result of rapid actions by the MHLW. The MHLW approved the new drug application for Soliris in April and listed Soliris for reimbursement through Japan's National Health Insurance system in June. On June 14, 2010, Alexion reported that data were presented at the 15th Congress of the European Hematology Association held in Barcelona, Spain, evaluating the substantial disease burden of PNH in patients enrolled in the International PNH Registry and, separately, in a South Korean PNH patient registry. Nephrology: Atypical Hemolytic Uremic Syndrome (aHUS) In April 2010, Alexion announced completion of enrollment in its current clinical studies to investigate Soliris as a treatment for patients with aHUS. The 26-week trials include adult and adolescent patients in two cohorts: those who had been treated chronically with plasma therapy, and others who were resistant or intolerant to plasma therapy. Preliminary data from the trials are expected to be presented near the end of 2010. The Company expects to begin a trial in pediatric aHUS patients in the fall of 2010. Additional early clinical experience with Soliris as a treatment for patients with aHUS was recently presented at the Second International Conference on HUS-MPGN-PNH held in Innsbruck, Austria and summarized in an announcement by the Company on June 15, 2010. Transplant: Acute Humoral Rejection (AHR) Soliris is being investigated as a treatment for patients undergoing kidney transplant who are at elevated risk of antibody mediated rejection, also known as acute humoral rejection, or AHR. The Company is supporting investigator-initiated studies in elevated-risk kidney transplantation in the U.S. and Australia and is planning a company-sponsored controlled clinical trial using Soliris to prevent AHR in patients undergoing kidney transplant. This study is expected to commence in multiple centers toward the end of the year. Positive interim data on 16 patients from an investigator-initiated trial at the Mayo Clinic was presented at the American Transplant Congress in May 2010. Oncology Program: Trial Enrollment Completed Enrollment is now completed in the Company's Phase I dose-escalation clinical study of samalizumab, its anti-CD200 antibody, in patients with treatment refractory chronic lymphocytic leukemia or multiple myeloma. The trial has enrolled approximately 25 patients. 2010 Financial Guidance: The Company is reiterating its previously announced 2010 financial guidance, including the upward revisions in 2010 guidance for revenues and non-GAAP EPS, and the narrowing of 2010 guidance for non-GAAP operating expenses, which were announced on June 2, 2010. In 2010, worldwide net product sales are expected to be within an upwardly revised range of $515 to $530 million, from the previous range of $505 to $520 million. Non-GAAP R&D expenses are anticipated to be in the range of $95 to $100 million and guidance for non-GAAP SG&A expenses have been narrowed from the previous range of $185 to $195 million to $190 to $195 million. As a result, 2010 guidance for non-GAAP operating expenses has been narrowed from the previous range of $280 to $295 million to $285 to $295 million. Cost of sales are anticipated to be in the range of 12 to 13 percent. The Company's share-based compensation expenses for the year are expected to be in a range of $32 to $34 million. The GAAP tax rate is expected to be in the range of 30 to 32 percent. The non-GAAP tax rate, which excludes non-cash tax expense, is expected to be in the range of 11 to 12 percent. Based on a forecast of 94 million fully diluted shares outstanding for 2010, Alexion is reiterating its non-GAAP earnings per share guidance in the upwardly revised range of $1.63 to $1.68, from the previous range of $1.60 to $1.65. Conference Call/Web Cast Information Alexion will host a conference call/webcast to discuss matters mentioned in this release. The call is scheduled for today, July 22, 2010, at 10:00 a.m., Eastern Time. To participate in this call, dial 719-457-2642, confirmation code 4227999, shortly before 10:00 a.m., Eastern Time. A replay of the call will be available for a limited period following the call, beginning at 1:00 p.m., Eastern Time. The replay number is 719-457-0820, confirmation code 4227999. The audio webcast can be accessed at www.alexionpharma.com. About Soliris Soliris is a first-in-class terminal complement inhibitor developed from the laboratory through regulatory approval and commercialization by Alexion. Soliris has been approved in the U.S., European Union, Japan and other countries as the first treatment for patients with PNH, an ultra-rare, debilitating and life-threatening blood disorder defined by chronic hemolysis, or the destruction of red blood cells. Prior to these approvals, there were no therapies specifically available for the treatment of patients with PNH. Alexion's innovative approach to complement inhibition has received some of the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad implications for future biomedical research and the 2009 Prix Galien France Award in the category of Drugs for Rare Diseases. More information on Soliris is available at www.soliris.net. About Alexion Alexion Pharmaceuticals, Inc. is a biopharmaceutical company working to develop and deliver life-changing drug therapies for patients with serious and life-threatening medical conditions. Alexion is engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic and kidney diseases, transplant, other inflammatory disorders, and cancer. Soliris is Alexion's first marketed product, and the Company is pursuing potential new indications for Soliris beyond PNH, as well as early-stage development of other antibody product candidates. This press release and further information about Alexion Pharmaceuticals, Inc. can be found at www.alexionpharma.com. This press release includes certain non-GAAP financial measures that are adjusted from GAAP figures. Alexion believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Alexion's past financial performance and its prospects for the future. The non-GAAP financial measures are included with the intent of providing both management and investors with a more complete understanding of underlying operational results and trends. In addition, these non-GAAP financial measures are among the primary indicators Alexion management uses for planning and forecasting purposes and for measuring the Company's performance. These non-GAAP financial measures are not intended to be considered in isolation or as a substitute for GAAP figures. A reconciliation of GAAP to non-GAAP figures is included in this press release. [ALXN-E] This news release contains forward-looking statements, including statements related to guidance regarding anticipated financial results for 2010, projected tax rates, assessment of the Company's financial position and commercialization efforts, including with respect to the expected commercial launch of Soliris in Japan, potential benefits and commercial potential for Soliris, potential of Alexion's complement-inhibition technology for treatment of diseases other than PNH; plans for clinical programs for Soliris in aHUS and other non-PNH indications and for samalizumab; and progress in developing commercial infrastructure. Forward-looking statements are subject to factors that may cause Alexion's results and plans to differ from those expected, including for example, decisions of regulatory authorities regarding marketing approval or material limitations on the marketing of Soliris, delays in arranging satisfactory manufacturing capabilities and establishing commercial infrastructure, delays in developing or adverse changes in commercial relationships, the possibility that results of clinical trials are not predictive of safety and efficacy results of Soliris in broader patient populations, the possibility that initial results of commercialization are not predictive of future rates of adoption of Soliris, the risk that third parties will not agree to license any necessary intellectual property to Alexion on reasonable terms or at all, the risk that third party payors (including governmental agencies) will not reimburse for the use of Soliris at acceptable rates or at all, the risk that estimates regarding the number of patients with PNH or other disorders is inaccurate, and a variety of other risks set forth from time to time in Alexion's filings with the Securities and Exchange Commission, including but not limited to the risks discussed in Alexion's Quarterly Report on Form 10-Q for the period ended March 31, 2010 and in Alexion's other filings with the Securities and Exchange Commission. Alexion does not intend to update any of these forward-looking statements to reflect events or circumstances after the date hereof, except when duty arises under law.   ALEXION PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(in thousands, except per share amounts)(unaudited)                 Three Months EndedSix Months EndedJune 30,June 30,   2010     2009     2010     2009     Net product sales $ 125,834 $ 92,256 $ 243,412 $ 173,523   Cost of sales (1) 13,721 10,313 27,720 20,272   Operating expenses: Research and development (1) 23,690 18,288 46,064 37,377 Selling, general and administrative (1)   56,098     42,705     106,733     79,357   Total operating expenses   79,788     60,993     152,797     116,734     Operating income 32,325 20,950 62,895 36,517   Other income (expense) (242 ) 339 (739 ) (84 ) Debt exchange expense   -     (3,395 )   -     (3,395 )   Income before income taxes 32,083 17,894 62,156 33,038   Income tax provision   10,310     1,092     19,449     1,730     Net income $ 21,773   $ 16,802   $ 42,707   $ 31,308     Earnings per common share Basic $ 0.24   $ 0.20   $ 0.48   $ 0.38   Diluted $ 0.24   $ 0.19   $ 0.46   $ 0.35     Shares used in computing earnings per common share Basic   89,002     85,128     88,755     82,948   Diluted   92,575     90,159     92,340     89,975       (1) The following is the share-based compensation expense included in the respective captions of the condensed consolidated statements of operations above:   Three Months EndedSix Months EndedJune 30,June 30,   2010     2009     2010     2009   Share-based compensation expense: Cost of sales $ 250 $ - $ 565 $ - Research and development 2,025 1,817 4,110 4,055 Selling, general and administrative   5,975     5,131     11,679     10,819   Total share-based compensation expense $ 8,250   $ 6,948   $ 16,354   $ 14,874             ALEXION PHARMACEUTICALS, INC.CONDENSED CONSOLIDATED BALANCE SHEETS(in thousands)(unaudited)   AtJune 30,December 31,   2010   2009 Cash, cash equivalents and marketable securities $ 248,825 $ 176,220 Trade accounts receivable, net 127,023 113,731 Inventories 57,747 40,885 Deferred tax assets 16,816 16,726 Other current assets 41,374 25,894 Property, plant and equipment, net 161,871 164,691 Deferred tax assets, noncurrent 181,095 194,308 Other noncurrent assets   54,843   53,946 Total assets $ 889,594 $ 786,401   Accounts payable and accrued expenses $ 84,730 $ 83,187 Other current liabilities 4,499 2,075 Long term debt 3,718 9,918 Other noncurrent liabilities   4,433   2,865 Total liabilities   97,380   98,045   Total stockholders' equity   792,214   688,356   Total liabilities and stockholders' equity $ 889,594 $ 786,401